Pliant Therapeutics, Inc. (PLRX) News
Follow Pliant Therapeutics, Inc. (PLRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Pliant Therapeutics gets FDA Fast Track for PLN-101095 plus pembrolizumab
Pliant Therapeutics (PLRX) receives FDA Fast Track designation for PLN-101095 when used in combination with pembrolizumab to treat ICI-refractory solid tumors.
REGULATION | Aug 18, 2026, 12:30 PM UTC
L
Pliant Therapeutics Q2 EPS $(0.36) Misses $(0.34) Estimate
Pliant Therapeutics (NASDAQ: PLRX ) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 49.3 percent increase over losses of $(0.71) per share
EARNINGS | Aug 11, 2026, 08:21 PM UTC
L
PLRX - Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PLRX - Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 11, 2026, 08:07 PM UTC